Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Receivables (2017 - 2025)

Historic Change in Receivables for UroGen Pharma (URGN) over the last 8 years, with Q3 2025 value amounting to $54000.0.

  • UroGen Pharma's Change in Receivables fell 9899.76% to $54000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year decrease of 13113.01%. This contributed to the annual value of $4.9 million for FY2024, which is 7740.05% up from last year.
  • Latest data reveals that UroGen Pharma reported Change in Receivables of $54000.0 as of Q3 2025, which was down 9899.76% from $11000.0 recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Change in Receivables registered a high of $5.4 million during Q3 2024, and its lowest value of -$2.7 million during Q3 2023.
  • Moreover, its 5-year median value for Change in Receivables was $11000.0 (2025), whereas its average is $666157.9.
  • Examining YoY changes over the last 5 years, UroGen Pharma's Change in Receivables showed a top increase of 30267.12% in 2024 and a maximum decrease of 50900.47% in 2024.
  • UroGen Pharma's Change in Receivables (Quarter) stood at $3.9 million in 2021, then decreased by 16.75% to $3.3 million in 2022, then decreased by 20.73% to $2.6 million in 2023, then tumbled by 196.3% to -$2.5 million in 2024, then skyrocketed by 102.16% to $54000.0 in 2025.
  • Its Change in Receivables stands at $54000.0 for Q3 2025, versus $11000.0 for Q2 2025 and -$664000.0 for Q1 2025.